The treatment of psoriatic arthritis and inflammatory spondylitis.
NSAIDs still remain the initial therapeutic modality for psoriatic arthritis and inflammatory spondylitis. Disease-modifying antirheumatic drugs have only been proven to be useful in peripheral arthritis, without efficacy in axial inflammatory spondylitis. In recent years, the introduction of tumor necrosis alpha inhibitors into clinical practice has produced a substantial impact in both peripheral and axial disease, with improvement in pain, function, and quality of life. Factors such as cost-effectiveness and safety will need to be better characterized over time.
Castro-Rueda
Hernan
H
Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA 92093-0943, USA.
Kavanaugh
Arthur
A
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D018836:Inflammation Mediators / Q000627:therapeutic use*; D013166:Spondylitis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology* / Q000503:physiopathology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000502:physiology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D018836:Inflammation Mediators; D014409:Tumor Necrosis Factor-alpha